Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Tanveer Tabish

PhD


BHF Advanced Fellow & Principal Investigator

We interweave the scientific fields of nanomedicince, biomaterials, tissue engineering, bioengineering and biochemistry to develop ‘personalised’ solutions based on light-mediated therapeutic modalities that utilise nanotechnology in treating many diseases such as cancer, wound healing, cardiovascular diseases, and central nervous system disorders. Our research interests include the novel synthesis of two-dimensional graphene-related nanosystems, controlled nanomedicine-based drug delivery platforms and mitochondria-targeted nanoassemblies through sub-cellular recognition processes. In the interdisciplinary space at the convergence of engineering, medicine and pharmaceutical nanotechnology, our research interests are broadly in the area of gas therapy and photodynamic therapy as well as photothermal therapy for cancer, infections and cardiovascular diseases. In collaboration with international colleagues, Dr. Tabish's research has primarily focussed on evaluating the pre-clinical efficacy of graphene-based nanomedicines in in-vitro, in-vivo and ex-vivo models of cancer and infections (see publications).

Our current research focuses on the role of nitric oxide in cardiovascular diseases and how endogenous and exogenous sources of nitric oxide can be manipulated for the treatment and prevention of cardiovascular diseases in a safe and targeted fashion. We also work in close collaboration with engineers, pharmacists, and clinicians to fabricate a novel first in class series of nanomedicines designed specifically to target cell's powerhouse 'mitochondria'. Besides expanding our knowledge of the fundamental crosstalk between the mitochondria and disease management, our work will also provide novel insights into the strategies for preparing mito(nano)drugs to destroy the cell’s powerhouse in a targeted manner. Targeting mitochondria with nanomedicines may represent a significantly important therapeutic target and potentially transform the conventional therapeutic interventions both philosophically and practically.